Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Type 2 Diabetes, Microvascular Dysfunction
Interventions: Intensive risk factor management; Other
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 85 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Cosmetic Techniques
Interventions: Restylane-L®, Restylane-L® Lyft, Restylane Silk®; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Infections, Meningococcal
Interventions: Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid), Placebo; Combination Product · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 16 Years to 18 Years
Enrollment: 945 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 49
States / cities: Phoenix, Arizona • Bell Gardens, California • Los Angeles, California + 35 more

Conditions: Urothelial Carcinoma, Bladder Cancer
Interventions: Durvalumab (Cohort 1-3), External Beam Radiotherapy (EBRT), Bacillus Calmette-Guérin (BCG), Gemcitabine, Docetaxel, Tremelimumab, Durvalumab (Cohort 4/5), To be determined, Intravesical NAI (Cohorts 6-7), Subcutaneous NAI (Cohort 8); Drug · Radiation · Biological + 1 more
Lead sponsor: Noah Hahn, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 9
States / cities: Phoenix, Arizona • Indianapolis, Indiana • Iowa City, Iowa + 6 more

Conditions: Newly Diagnosed Operative Invasive Ductal Breast Carcinoma Stage I-II
Interventions: Vitamin D; Dietary Supplement
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Blood Pressure
Interventions: Blood Pressure Readings on B40 Patient Monitor; Device
Lead sponsor: GE Healthcare; Industry
Eligibility: 3 Years to 75 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Louisville, Colorado

Conditions: Pancreatitis
Interventions: Abstats sensor; Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hallux Valgus
Interventions: conventional surgical technique - Chevron-type distal metatarsal osteotomy, minimally invasive surgical technique; Procedure
Lead sponsor: Henry DeGroot, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Newton, Massachusetts

Conditions: Erectile Dysfunction, Impotentia Erigendi
Interventions: 3D-Erect; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: ADHD, Controls
Interventions: Lidocaine gel, Placebo, Injected lidocaine; Drug
Lead sponsor: PhenoSolve, LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Breast Cancer
Interventions: Ultrahypofractionated Radiation, Moderately Hypofractionated Radiation; Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Loveland, Colorado • Jacksonville, Florida • Voorhees Township, New Jersey + 2 more

Conditions: Ischemia
Interventions: CT and stress test; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 5
States / cities: Overland Park, Kansas • New York, New York • Columbus, Ohio + 2 more

Conditions: Spontaneous Ventilation
Interventions: noninvasive positive pressure ventilation; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cancer
Interventions: ziv-aflibercept; Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Sinusitis
Interventions: RS-Series Rhinosinusitis Treatment System, FinESS Balloon; Device
Lead sponsor: Entellus Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 13
States / cities: Fresno, California • Evanston, Illinois • Maywood, Illinois + 10 more

Conditions: Degenerative Disc Disease
Interventions: CALIBER; Device
Lead sponsor: Globus Medical Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Miami Beach, Florida • Charlotte, North Carolina

Conditions: Quantitative Validation of Imaging System
Interventions: Not listed
Lead sponsor: Chandan K Sen; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Fat Disorder
Interventions: BTL-899; Device
Lead sponsor: BTL Industries Ltd.; Industry
Eligibility: 22 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Chicago, Illinois • Hunt Valley, Maryland

Conditions: Intermediate Risk Non-Muscle Invasive Bladder Cancer
Interventions: Nadofaragene Firadenovec; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 57
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more

Conditions: Fever, Mycoses, Neutropenia
Interventions: FK463; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Surgery
Interventions: BlockSynop surface electromyography device, Peripheral nerve block; Device · Procedure
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 0 Years to 21 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Drug-Resistant Epilepsy, Epilepsy, Epilepsy (Treatment Refractory), Epilepsy Comorbidities, Epilepsy, Drug Resistant, Epilepsy, Generalized, Epilepsy, Focal
Interventions: Target optimization using LIFU, Serial LIFU stimulation; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Thoracic Diseases, Postoperative Pain, Opioid Use
Interventions: Liposomal bupivacaine, Bupivacaine Injection; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cancer, Malignancy, Malignant Neoplasm, Neuropathy, Neuropathies Sensory, Chemotherapy-induced Peripheral Neuropathy
Interventions: Neurosensory testing with Pressure-Specified Sensory Device; Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Less Invasive Detection and Treatment of Very Early Coronary Artery Disease in Patients With Diabetes Mellitus

Prospective Evaluation of Facial Cosmetic Procedures

Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Vitamin D3 (Vit D3) Supplementation and T Cell Immunomodulation in Patients With Newly Diagnosed Operative Invasive Ductal Breast Carcinoma

B40 Non-Invasive Blood Pressure Equivalency Study

Abstats: Computer-aided, Non-invasive, Acoustic Gastrointestinal Surveillance (AGIS) in Acute Pancreatitis

Prospective Trial of Minimally Invasive Surgery Versus Standard Surgery for Correction of Hallux Valgus

External Device for Erectile Dysfunction (3D-Erect)

Validating a New Non-invasive Approach to Testing Lidocaine Effectiveness

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer

Dual Energy CT for Ischemia Determination Compared to "Gold Standard" Non-Invasive and Invasive Techniques

EIT Assessment of Lung Volume and Tidal Distribution: A Comparison of Non-Invasive Ventilation Devices

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Balloon REmodeling Antrostomy THErapy Study

Study of an Expandable Interbody Device for the Lumbar Spine

Non Invasive and Non-Contact Imaging Of Tissue Oxygenation and Vascular Reactivity

Non-invasive Lipolysis and Improvement of Muscle Tone in Upper Arms

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia

Peripheral Regional Blockade and EMG

Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy

Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial

Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy